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Fluids that accumulate at wound sites may be an 
important reservoir of growth factors that promote 
the normal wound healing response. The presence of 
heparin-binding growth factors was studied in burn 
wound fluid (BWF) from 45 pediatric patients who 
had sustained partial thickness burns. One of the 
growth factors present was similar to platelet-derived 
growth factor (PDGF) based on its heparin affinity, 
inhibition of bioactivity by a PDGF antiserum, and 
detection in a PDGF-AB enzyme-linked immunosor-
bent assay. A second growth factor was identified 
as heparin-binding epidermal growth factor-like 
growth factor (HB-EGF) based on its heparin affinity, 
competition with 12sI_Ia beled epidermal growth fac-
tor (EGF) for EGF receptor binding, and recognition 
in biological assays and Western blots by two HB-
EGF antisera. Amino acid sequence analysis of one 
H eparin-binding epidermal growth factor-like growth factor (I-IB-EGF) was first described as a macropl~age secr~tory protein that bill~s .strongly to hepann and stimulates DNA syntheSIS III fibro-blasts and vascular smooth muscle cell s [1] . Puri-
fication of HB-EGF and cloning of its cD NA fi:om the U937 
macrophage-like cell line re veal ed that HB-EGF is a member of the 
epidermal growth factor (EGF) family [2 ,3]. Structural similarities 
of members in this group include three intra-chain disulfide bonds 
that result in an appropriate protein conformation for binding and 
activating EGF receptOl's (EGF-R) [4] . Between the first and sixth 
cysteine residues, human I-IB-EGF shares 40 - 53% homology w ith 
human EGF, transforming growth factor-a (TGF-a ), and amphi-
reguLin (An..) (2J . There is conside rable cross-species conservation 
of the I-IB-EGF protein , with approximately 85- 90'X, homology 
between the amino acid sequences of hul11an, monkey, pig, rat, and 
mouse HB-EGF [2,5-7] . In common with several EGF family 
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form of this second growth factor verified its identity 
as an N-terminally truncated form of HB-EGF. Im-
munohistochemical analysis of partial thickness 
burns demonstrated the presence of HB-EGF in the 
advancing epithelial margin, islands of regenerating 
epithelium within the burn wound, and in the duct 
and proximal tubules of eccrine sweat glands. HB-
EGF in the surface epithelium of burn wounds was 
uniformally distributed, whereas it was restricted to 
the basal epithelium in nonburned skin. These data 
support a role for PDGF and HB-EGF in burn wound 
healing and suggest that the response to injury in-
cludes deposition of HB-EGF and PDGF into blister 
fluid and a redistribution of HB-EGF in the surface 
epithelium. near the wound site. Key words: wou"d 
healing/partial thickness bltl'll/epithelium/skin. ] Invest DeJ'-
matol 106:49-56, 1996 
m embers, HB-EGF is predicted to be synthesized as a transmem-
brane precursor (208 al11ino acids) frol11 which mature HB-EGF 
(approx. 86 amino acids) appears to be released by extracellular 
proteolytic cleavage [2 ,3]. The human HB-EGF precursor is a 
binding site for diphtheria toxin [8] that may also directly bind and 
activate EGF-R on n eighboring cells in a juxtacl·ine fashion. 
HB-EGF and AR are distinguished fi'ol11 other EGF family m embers 
by their ability to bind strongly to heparin , a property which m ay 
result in their extracellular regulation by cell surface heparin-like 
molecules [9-11]. 
I-IB-EGF mRNA has been ide ntifi ed in multipl e cell types 
including macrophages, vascular smooth muscle cells, endothelial 
cell s, eosinophils , and endometrial epithelial cells [2 ,12-1 5]. Re-
verse transcriptase polymerase chain reactions (R T -peR) and 
Northern blotting have shown wide tissue distribution ofHB-EGF 
mRNA including skin, lung, heart, kidney, skeletal muscl e, brain, 
male reproductive system, lymph node, thymus, and sp leen [5,6] . 
Also, we have recently cloned a 380-bp HB-EGF cDNAfrom 
porcine uterus and plll-itied HB-EGF from pig ute rine tissues and 
secretions [7] . Target cells for HB-EGF include ftbroblasts, smooth 
muscle cells, and keratinocytes [1,2] . 
HB-EGF may playa role in wound h ea ling, since it is produced 
by and acts on cells that are involved in the WOll11d healing process 
(i. e., m acrophages, fibroblasts, and keratinocytes). From previous 
studies, a potential role for endogenously produced growth factors 
at the wound site has been inferred by their presence in wound 
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fluid. Pl atelet-derived growth facto r (PDGF)-like mol ecules have 
been documented in wound fluid collected f1-0111 surgi cal drains 
afte r mas tectomies and orthopedic surgery [1 6 -1 8], and from 
partial-thickn ess excision al porcine wounds [19]. The in creased 
rates of coll agen synth esis and re-e pithe liali zation of superficial 
wounds cove red with occl usive dressings have bee n attJ-ibuted to 
the dressing maintaining high local concentrations of growth 
f.,c tors produced at the wound site [20]. Wound fluid obtained 
£i-om beneath occl usive dressings stimulates prolife ration of cul-
tured endothe lial cell s and dermal fibrobla sts [21] and co ntain s 
EG F, PDGF, tumor necrosis f:l ctor-a, and basic fibrobla st growth 
facto r [22 ,23). 
Since a detail ed analysis of the growth fa cto rs that accumulate in 
bli ste rs arising £i'om partial thickn ess burns has not previously been 
reported , we characterized those that are present in burn wound 
fluid (BWF) up to 6 d after the initial burn injmy. H ere, we show 
that two of the principal fibroblast hepa rin-bindin g growth factors 
in BWP arc PDGF and HB-EGF, and w e describe th e immunohis-
tochemical localization of HB-EGF in the vicinity of th e burn 
wound. 
MATERJALS AND M ETHODS 
Collection of Human BWF BWF was o btained li'om 45 pediatric 
patients (approximately H mo to 16 y of age) who had suffered acc idcuta l 
thermal injury. Intact bli ste rs of partial thi ckness burns were aspirated up to 
6 d after injury (day 0 = da y of burn) and the Huid was co ll"ctcd. poo led , 
and frozen at - 20°C. Inl'o rmed consent was obtained for each patient. The 
stud y protocol confo rmed to the ethi cal guidelines of the Human Subjects 
R.esea rch Committee of the C hildren 's Hospital R.esea rch I' o undation. 
Characterization of growth factor activities ill BWF 
H Cjln";I/-A.//il/il)' C hmllllllogrnphl': 13 WF was clarified by centrifu gation 
('I 2,OOOg for 30 min) and passage through O.4S-J..I.m mcmbrane filters. It was 
then diluted '1 O-fold in 20 mM Tris H C I (pH 7.4) and appli ed at 1- 3 ml / min 
to an EconoPac heparin "frinity column (0.7 X 3.6 cm; l3ioR.ad Labo rato-
ries. Richmond . C A) or a TSK heparin 5PW column (0.75 X 8 cm ; 
TosoHaas, Philadelphia , PA) that had been equilibrated in 20 111M Tris H C I 
(pI-I 7 .4) contnining 0. 2 M NaC I. A fa st protein liquid clnomatograph y 
(FPLC) system (l'harlTla cia LKB Biotech Inc., l', scataway, NJ) was used to 
appl y the sample, to wash the column w ith equilibration buffer until thc 
abso rbance (A2HO) of the elLw te was constant . and to gene z:ate a 40-ml 
gradient of 0 .2- 2.0 M NaC I fo r eluti o n of bound proteins fro III the co lu111n. 
During protein e lution, the Ho w rate was 1 1111 / min and the eluate was 
co ll ected into fo rty 1-1111 fracti o ns which w ere assayed for their ability to 
stimula te CI-IJthyrn idinc incorporatio n in Balb /c 3T3 ce ll s o r to compete 
with ' '' I- labeled EGF C2' I- EGF) fo r binding to th" EGF-R.. 
G rollllh Fnelor AsslI )'s : Aliquots of column fi'actions werc tested for the ir 
"bili ty to stimulate r:J H) th ymidille incorporation into DNA of conHuent 
quiescent Bnlb/c 3T3 ce ll s [J]. Samples were al so tested in an EGF 
radio recepto r assay (IUtA) using human cndometrial carcinoma cells 
(HEC- l-B) [1 0J. S0 111 e EGF R.n..As w ere performed by incubating H EC-
1-13 cell s in binding medium that contained either 10'Vo, (vol /vo l) I-ffi-EGF 
goat antiserum or 10'Y" (vol /vo l) goat pre-immune se rum as described 17 J. 
Measurement of PDGI' -A13 was performed using a human PDGF-AI3 
Quantikine double sandwich enzyme-linked illlJ11ulloso rbent assay (ELISA) 
detectio n kit (R.& D Systems. Minneapo lis. MN). 
50S-PAGE nlld Wes lem BIM A llnl)'s is: O ne milliliter of burn Huid (days 
1-4) was centrifuged at 12.000g for 30 min and the supernatant filtered 
through 0.2-1.L1n membran es . The liltrate was diluted 1 O-fold in 10 mM Tris 
H C I/O.S M NaC I (pH 7.4) and passed thro ugh a 50-pJ bed o f he parin-
Scpharo se (Pharmacia LKB l3iotech). The heparin-Sepharose beads w ere 
washed extensively with 10 mM Tris H C IIO.S M NaC I (pH 7.4) prior to 
extraction o f bound prote ins by additio n of 50 J..I.I of 2X sodium dodecyl 
sul fate-po lyacrylam ide gel (SDS-PAGE) sample buffer. Burn Huid samples 
were run in p:Jralie l 011 dupli ca te 18%, SDS-PAGE under reducing conditions 
[11 and the electrophoresed proteins were Western blo tted as desc ribed [7]. 
T he ni troce llulose blots w ere blocked [24) and incubated overnight at 4°C 
with eithe r a 1 :5000 dilutio n of rnbbit anti serum raised aga inst the peptide 
KGLG KKJU) I'C LKKYKD corresponding to res idues 26-4 '1 of mature 
human HB-EGF (sec 11 0] fo r numbering system) or w ith a 1 :5000 dilution 
of pre-immune rabbit serum. Immunoreactive bands were developed by 
successive incuba tion of the blots with biotinylated anti-rabbit JgG (Ame r-
Sh'"11 Corp ., Arlington H eights. IL), streptavidin-alkaline phosphatase 
(All1ersham) and nitro-blue tetrazoliul11/S-broIll0-4-chloro-3-indo lyl phos-
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Phate (Life Techllo logics Inc .. Grand Island. NY) as desc ribed 17J. T his 
protocol was repeated on 330 J..I.I of a da y 3 and day 6 pooled BWF sample 
obtained fro m three piltients for w hich the Weste rn blot was incubated with 
10 J..I.g/ml of afrinity-purified HJ3-£GF antiserum or norma l rabbit IgG. 
Sequence-grade recombinant human HB-EGF was used as a standilrd on 
Western blots and was produced en o ur laboratory essentiall y as described. I 
Affinity Purification of Anti-HB-EGF(21-46) Antiserl1l11 The pcp-
tide HB-EG F(26-41.) was produced o n a Syne rgy 432A Peptide Syn thesizer 
(Applied Biosystems, Norwalk. CT) and puril1ed by C I K reve rse-phase 
HPLC. Approximately 'l mg of the peptide was di ssolved in 0.2 M NaH COJ 
conta ining 0.5M NaCI (PH 8.0) and coupled to ai-ill] NH S-activatcd 
HiTr'lp co lumn (Pharm;lcia LKB Biotech) accordin g to the m ,muf' lcturcr's 
specifications. l-ll3-EGF an tiserum was diluted 10-lold in PJ3S ilnd cycled 
through the column three times, after which the co lumn was washed ",ilh 
20 ml of PBS foHowed by 20 ml of PBS/O .S M N aC I. 130und proteins wcre 
eluted using 0. 1 M gly,ine (pH 2 .5) and co llected in to O.S-m l f;'a ctio ns that 
were immediate ly ne utralized with 50 /1.1 of I M Tris . IgG concentrations or 
individual fractions were calculated from their absorbance at 280 n111. 
Purification of HB-EGF frOI11 BWF 
H epnri/l 1I!fillil), C hrolllnlllgmph)': Two hund red milliliters of I3WF was 
subjected to heparin affinity chromatography using nn EconoPac heparin 
FPLC column as desc ribed above. Biologicall y active fra ctions tha t con-
tained the 0.6-1.3 M NaC I eluate w ere diluted 5-fo ld in 20 mM Tris Hel 
(pH 7.4) and subjected to a second step of heparin afrini ty chro llliltograph)' 
using" TSK heparin 5 l'W FPLC column as described above. Fr'lctions 
containing the 1 .0 -1. 2 M NaC I eluate were pooled (4.5 ml) and subjected 
to reverse-phase high-perfo rmance liquid chromatography (HPLC ) . 
Rcverse-Pitnsc HPLC : R.cver se-phase HPLC was peri-armed on a Hitachi 
I-IPLC system using a V)'dac C. co lumn (0.46 X 25 em , 5-J..I.ln particle size; 
The Sepanltions Group , H esperia , CA) as described [7 1. Bound pro teins 
were eluted fro In the colulun 'with a 1l1ul t.ilincar organi c grad ient cOlnprising 
5-15% aceton itrile over 5 min , 15-40% aceton itrile over :1 20 min. and 
40 - 90% over ·1 min. T he column e lu ate was monitored at 214 nm using an 
in-line ultra vio let (UV) detector and the ch romatogram was archi ved as 
desc ribed 12 5]. Indi vidual fra ctions (1 ml) we re co llected in silico ni zed tubes 
containing NaOH to neutrali ze the T FA . Two-microliter aliquots of 
selected fra ctions were diluted 10-fo ld in PUS con ta ining '1 % bov ine seru\l1 
albumin and assayed for mitogenic activity on 3T3 ce lls. Three-microliter 
aliquots o f se lected fi'actions were assayed directly in the EGF R.ltA. 
A /I';IIV A cid Seq/le/l cil/g: Five picomo les o f a reverse-phase purilied bioac-
tive pro tein peak were subjected to N-terlllinal amino acid seque ncing fo r 
10 cycles using an Applied Biosysterns Mo de l 470A gas phase sequenator. 
Phenylthiohydantoin amino acid derivati ves were identified b ), C I 6 reverse 
phase HPLC. 
Immunohistochemical Detection ofHB-EGF in Burn Wounds 
Tiss /l e Procl/re.IICIII: In accordance w ith the ethi cal g uidelines o f ti, e I-Iuman 
Subjects R.esearch Committee of the C hildre n's Hospital R.esea rch FOUll-
dati,on, human bum wo und tissues on da y 2 and d 'IY '1'1 w ere procured fro 111 
th e leg of two patie nts at the time of exc ision and grafting of full thi ckness 
burns ill the operating r00I11 . Durn spcc inlcns utili zed in thi s study were 
li'om the burn wound margin and contained a rim of normal e pidermis and 
underl ying de nnis. N onburned norm,t1 chest skin was obtained at the tillle 
of "utopsy of a difFerent pediatric patient. Tissues were immediatel y placed 
in icc-co ld Dulbecco 's modified Eagle 's medium prior to snap-fi'eezing ill 
Tissue-Tek OCT C ompound (M iles Diagnostics, Kankakee. IL) and sto red 
at - 70°C. Frozen sections we re 111o Ul1 tcd . \vet- fixed in a 5011.1 acctoll c/SO% 
methano l solutio n for 5 min , and rin sed ~cvc ral tilll es ill PI3S. 
illllll II 1I0it is/arit elll isl.},: All immunohistochem ical reactions were pe rformed 
at room temperature in a humidi ty chambe r. T issue sections were blocked 
with 10% normal goat Serum (Vector Laboroto ri es Inc., l3urling alll e . C A) in 
PBS for 20 min and then incubated for 60 min in the same solution 
containing 1:1 00 dilutio llS of 1-113-EGF(26-41) antise rum or preimlllunc 
serum , o r 19 J..I.g/ml of affi nity-purilied anti-HB-EGF(26-41) or no rm al 
rabbit I.gG. Sec tions were dipped 10 rimes in PBS/ O. l "/0, Tween 20 followed 
by three 3-l1lin rin ses with PBS. Th ey we re then incubated in a 1: ·100 
dilution of biotillylatcd goat anti-rabbit IgG (Vecto r Labo ratories Inc .) in 
2% normal goat serum for 30 min, was hed as described above, and then 
incuba ted in a I :1 00 dilutio n ofstrcp tavidin Auorescc in (Vecto r Labs Ine. or 
Amcrsham Corp .. Arlington Heights. IL) in 2% no rmal goat serum lo r 30 
I C ri ssman-Combs MA , I3rigs tock DR. Uesner GE: Mol Bioi C rlI4(suppl): 
A 109. 1993 ("bst .) 
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Figure 1. B io logically active PDGF and HB-EGF arc present in human BWF. II) 13\1iIF aspir:lted 6 d afi:er iIDUI)' fi'om the blister ofa partial thickness bum 
was clarified by cemrifugation at 1 2.000,~ for 10 min and the supematant assayed for its abi lity to sti l1lulate DNA symhesis in na lb/c 3T3 cells, Em". hnl's. SD; triplicate 
determinations of i"H ithYl1lidine incorporation (e), h) Twelve m illiliters of U \1iIF aspirated fi'ol1l intact blisters of partial thickness bums were chllifled by 
cenllifugation and j'i ltration , T he supernatant was dil uted I U-fo ld in 20 111M Tris H CI (pH 7.4) and applied to an EconoPac heparin colu llln which was 
then developed \,\~th a U,2-2 M NaC I !,'1'adicnt, Ind ividua l fi'actions were tested at 5 pJ for their sLimulation of i." Hlthymidine incorporation in 3T3 ce ll s (e) , The 
same fi'actiom were tested at (c) 25 p.l fo r their abi li ty to compete with ' "' I- labeled EGF for binding to the EGF-rt (0 ) and (") 200 p.l for the presence of 
immunoreactive PDGF-A13 using a donble sandwich ELISA (0), t') Seven mi lli liters of U\1iIF prepared as described above were diluted j()-fold in 20 mM Tris H C I 
(pH 7.4) and applied to a TSK heparin Fl'LC column , The figure shows the stimnlation of:lT3 cell DNA synthesis by 25 p,1 of individual fi'a ctions in t.he presence 
(0 ) 0 1' absence (e) of 1 0 p,g/ m l ne utnl lizing antiserul11 to PDGF,) Twenty-five millili ters of 13WF fi'om a day I patient w as subjected to EconoPac heparin affinity 
chromatography as described above, An EGF R.RA was perfonned in binding med ium containing IO'y., (vollvol) of either gOnt pre-immune serum (0 ) or goat 
anti-I-JJ3-EGF amise rulll (_) plus 25 p,1 of fi'actions 9-25 which contained tlt e 0,6-1,3 M NaCI el uate. Resul ts are expressed as percent.age of maxlmal specific 
125I_EGF binding, 
52 M cCARTHY £7" f l L 
min. The specimcns were then washed, mounted using Aquamount (Lerner 
Laboratories, Pittsburgh, PAl , and examincd by Auorescence microscopy. 
RESULTS 
Human BWF Contains PDGF and HB-EGF BWF stimulated 
el-I)thymidine incorporation in Balb/c 3T3 cells in ;1 dose-depen-
dent manner (Fig la) . When a 12-ml pool of 13WF fi·om several 
patients was subj ected to hepa .. ·in a!tinity chromatography, two 
main peaks of eI-l)thymidine incorporation- stimulating activity 
were detected that were eluted from the column by 0.5- 0.7 M 
NaCI (fractio ns 9-14) and by 0.8-1.2 M NaCI (fractions 16 - 24) 
(Fig 1/.). When these fractions were tes ted in an EGF R.RA, a 
competitor of 1 251_EGF binding was present in the 0.8-1.2 M NaCI 
elu ate (Fig Ie) that co-eluted with the second mitogenic peak, 
suggesting that they might be shared properties of the same 
molecule. In contra st, the fractions co ntaining th e 0.5-0.7 M NaCI 
eluate were inactive in the EGF RRA, suggesting that they did not 
contain an EGF-R ligand. Since the heparin-binding property of the 
first mitogellic peak was comparable to that ofPDGF [26), fractions 
were tested in a PDGF ELISA w ith the result that immuno reactive 
human PDGF-AB was detected in the 0 .5-0.7 M NaCI eluate (Fig 
ltl). Fractions from heparin-affinity ch romatography of a different 
7-mJ pool of BWF were also assayed for 3T3 cell-stimulatory 
activity in the presence and absence of a neutra liz ing PDGF 
antiserum. As a result the mitogenic activ ity of fractions containing 
the 0.5-0.7 M NaCI eluate was reduced suggesting that at least one 
biologically active isoform of human PDGF (AA,B13 or All) was 
present (Fig Ie). The mitogenic activ ity of the 0.8-1.2 M NaCI 
eluate was somewhat enhanced by the POGF an tiserum , suggesting 
the second mitogenic peak was not PDGF-Jike and that it was able 
to interact synergisticaUy o r additively with non-lgG components 
of the antiserum. 
To eva lu ate more specifi caUy w hether I-l13-EGF was present in 
BWF, ti·actions obtained by hepari n affin ity chromatograph y of 
25 ml of day 1 13WF were tested in an EGF RRA .in the presence 
of a H13-EGF goa t antiserum that blocks EGF receptor binding 
by H13-EGF but not by EGF, TGF-a, or AR [7) . W he n tested in 
this mann e r, the 0.8-1.2 M NaCI e luate reta ined its 1251_EGF_ 
competing activ ity in the presence of pn: immun e serum but was 
rendered in effective in th e presence of the H13-EGF antiserum 
(Fig lj) . 
T he presence ofEGF-R ligan ds in13WF taken on day 0,1,2, 
3, 4, and 6 was shown by the abi li ty of crude (i .e., unpuri fied) 
samples to inhibit 1251_EGF binding by 18-42°;'. when tested in 
the EGF RRA at 0.066% (vol/vol) (data not shown). To test 
w hether thi s efFect was due, at least in part, to HB-EGF, 1-ml 
BWF sampl es were passed through mini-heparin columns and 
bound pmteins were subjected to SDS-PAG.E fo ll owed by 
Western blotting using a rabbit antiserum raised aga in st the 
peptide HB-EGF(26-41) . Th is antiserum, which recognizes 
human HB-EGF but not EGF, TGF- a, or AR (data not shown) , 
detected multiple imm un oreactive bands of Mr 10,000-15,000 
in a day 1 BWF sample t hat were not detected by pre-immune 
rabbit serum (Fig 2a). To co nfirm and extend thi s data , Western 
blotting was repeated using 13WF collected between day 1. and 4 
from fo ur othe r patients. As shown in Fig 2", similar immuno-
reactive bands we re detected in burn fluid o n each of the days 
tested. T he apparen t sizes of the proteins were clea rl y di stinct 
from those of 20- to 22-kDa native HB-EGF [2) an d m ore 
closely resembl ed that of no nglycosy lated H13-EGF such as the 
recombinant form of the protein produced in Escherichia co li . 1 In 
view of the concern that these immunoreactive proteins might 
not be authen tic forms of HB-EGF, the I-lB-EGF antiserum was 
affi n ity purified and the immune (bound) fract ion inc ub ated on 
a Western blot of day 3 and 6 13WF that was pooled from three 
different patients. As shown in Fig 2e, the purified antiserum 
rea cted strongly with 12-kDa recombinant hum an I-l13-EGF as 
well as with mu lt ipl e proteins in 13WF of approx im ate ly 10-16 
kDa; normal rabbit IgG tested at the same concen tration fa il ed to 
react with eith er the human I-IB-EGF sta nd ard or the protein s 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
M,x10·3 a 
69.0 
46.0 
30.0 
21.5 
14.3 
M,x10·3 c 
69.0 
46.0 
30.0 
21 .5 
14.3 
6.5 
b 
2 2 3 456 7 8 
2 3 4 
Figure 2. Hcparin-purificd BWF contains immunoreactive HB· 
EGF proteins. Aliquots of day 1-4 BWF was prepared and passed through 
mini-heparin columns as described in "'/fl lerifll fllld Met!tods. Bound proteins 
wcre extracted using 2X SDS-PAGE sample buffer and were electropho-
resed 0 11 duplica te 18'% SDS-polyacrylamide mini-gels. Proteins werr 
transferred to nitrocel lulose which was thcn blocked and incubated with 3 
·1 :5000 dilution of eithcr rabbit anti-H13-EGF(26-41) or rabbit pn:_inlI11Ullr. 
SCfl1l11. Inl111unorcaccive bands were v isuali zed by success ive in c ubations 01 I 
the blots with biotinylatcd goat anti-rabbit IgG. strepta vidin-alkalinc phos-
phatase and chromogenic substra tes. The figure shows (n) BWF from day I 
analyzed with pre-immune serum (/t/lle I ) or anti-HB-EGF(26-41) (/flllr 2) 
and (b) BWF from day 1 ( /filles I tlllI/ 5: different paticnt to that in [n]) , day 
2 (Inll es 2 nlld 6), day 3 ( /filles 3 nlld 7), and day 4 ( Itl ll es 4 n",/ 8) treated with 
pre-immu lle serum ( Inlles 1-4) or HB-EGF 'lIIti serLlm (lalli·s 5-8). Each 
sample lane received heparin-bindi ng protcins dcrived fi·om 400 ILl ofBWF. 
The figure also shows (c) the equivalcllt of 1 65 p.1 of heparin-purified day 3 
and day 6 pooled I3WF (lnlles J nlld 3) and 100 ng recombinant human 
HB-EGF (/(///I's 2 fl lld 4) incubated with 10 ILg/ml of normal rabbit IgG (!t1l1l'1 
1 fllld 2) or affin ity-purified anti-HB-EGF(26-4 1) ( /fill es 3 fl lld 4). 
detected in BWF (Fig 2c) . T h ese data thus provided further 
evidence that t he immunoreactivity in 13WF represen ted gen u-
ine focms of HB-EGF, despite theil· lowel· mass. 
HB-EGF Isolated from BWF Is Highly Truncated at Its N 
Terminus A lth o ugh use of two differell[ HB-EGF antisera 
pl·ovided strong evidence for the prese nce in BWF of H13-EGF 
rathe r than AR, to o b tain definitive proof we e lected to iso late 
and molec ularly c ha racterize th e g rowth facto r in qu estion. 
Preparati ve heparin afrll1.ity chromatograp hy was performed on :I 
200-1111 pool of BWF from two patients o n day 2 and 3 using an 
EconoPac heparin co lu mn fo llowed by a TSK he parin 5PW 
co lu111n (Fig 3a) . T he active fractions con ta ining th e 1.0-1.2 M 
NaCI e lu ate we re pooled and applied to a C 4 reverse-phase 
HPLC co lumn that was developed with a multilinear acewnitl-ile 
gradient. The co lu111n e luate con tained three activ ity peaks with 1 
retentio n tim es of 38 min, 42- 46 min , and 48 min thac were 
dete cted in both biologica l assays (Fig 3") . Altho ugh multiple 
prote in peaks were eluted fr0111 th e co lumn during this time 
co urse, o nl y the protein with a retention time of 42- 43 min was 
present in sufii cient quanti ty for stru c tural analysis. When 
approximately 5 plUo l of this protein were subj ec ted to 10 cycles 
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Figure 3. Isolation of HB-EGF from BWF. n) A pool of 200 ml of 
BWF from obwilled from two patients 0 11 day 2 and 3 was subjected to two 
cycles of affin ity chromatography using EconoPac- alld TSK-hepanll col-
umns. T he fi gure shows the absorbance (280 nm) of the eluate (solid line) 
when the TSK heparin column was developed with the illdica ted NaCl 
gradient (- - -) , and the stimulation of3T3 cell D NA synthesis by 3 l.tI (e) 
and inhibi tion of 1251_EG F binding by 5 ILL (0 ) of 1- 1111 fra tions collected 
during protein elutioll . Fractions containing the 1.0-1.2 M NaCl eluate 
were pooled (approx. 4.5 ml) and subjected to C. reverse-phase HPLC. II) 
Elution frO I11 the C. column of protein (Ao1. ) (---) between 30 and 72 min 
afte r sample inj ection (approximately 20 - 27':;', acetonjtrile [- - - ]) and the 
stimulation of 3T3 cd l DNA synthesis by 2 ILL (e) and inhjbition of 
12sl_EGF bindjng by 1 ILL (0 ) of the fractions collected over this time 
course. ' T he protein peak selected for amillo acid sequencing. 
of N-tennin al degrad at io n, n o amino ac ids we re id e ntified in the 
firs t cycle, three were identi fie d in th e second cycle, two we re 
identi fie d in th e third cycle , and o n e was id ent ifi ed in each of th e 
remaining seven cycl es (Table I). T h e last seven amin o acids 
were ide nti cal to res idues 28 - 34 of hum an HB-EGF (Table I) . 
W ith thi s alignment, the Lys residue id en tifi ed in the second 
cycle m atch ed th at in positio n 26 of h uman HB-EGF. Al th o ugh 
this alignment resu lted in a mism atch be tween residues id enti-
fie d in th e third cycl e (Le u or Tyr) and positio n 27 o f human 
HB-EG F (Gl y) , thi s w as pro babl y du e to a sequ en cin g e rro l' . I t is 
of n ote th at the Le u , Lys, Asp , and Pro residues de fini tively 
iden tifi ed in the 4 th , 7th , 9th , and 10th cycl es, respective ly, 
clearl y dist in gui sh thi s peptide sequ en ce as o ri g in ating fro m 
HB-EGF rathe r th an AR (Table I). 
The Distribution of HB-EGF in Burn Wounds Is Different 
from That in Normal Skin Excision o f a day 14 burn wound 
and its m 'lrgin demonstrated positive staining of the en tire epithe-
lium at the unburned margin and of keratin ocytes within a 
regeneratin g island fro m a hair fo llicle whe n in cubated with 
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Table I. N -Terminal A m ino A cid S e quence o f BWF 
Grow th Factor Demonstrates Its I d entity as a Truncated 
F orm o f HB-E GF" 
BWF[l - 10] HB-EG F[25-34] AR [30 - 39] 
Xaa Gly Gly 
Lys,Gly,Ser Lys Gly 
LClI ,Tyr Gly Lys 
Leu Leu Astl 
Gly Gly Gly 
Lys Lys Lys 
Lys Lys Asn 
Arg Arg Arg 
Asp Asp Arg 
Pro Pro Asn 
,I Fractions conlaining the 43- to 46-min H PLC-p urificd bio:tcovc peak (sec F ig 3/1) 
were pooled ~11I d reduced in volume to approximately tOO J.tI . The sample (approx. 5 
p111o l) was then subjected to aurom"tcd I-terminal amino :'Icid sequence analysis . The 
table shows rhe amino adds that wcre identified in c~l ch Oflh t.! first LO cycles ofEdmrtn 
degradatioll . Also shown is the align11le n t of the sequence with that of an in ternal 
domain of I111111 :1 11 J-I13-EGF (residues 25-34) and the correspondin g d01n:lin of hul11:ltl 
An.. (rcsiducs 30-39) . 
HB-EGF(26 - 41) an tise.rum . T his pattern of staining was absent 
w hen an adj acen t ti ssue section was treated ",ri th pre- imm une 
serum (data no t shown). To verify these fi ndings, immunohisto-
che mistry was repeated o n the sam e burn specim en using afi-inity-
purified HB-EGF(26 - 41) with w hich immunoreactivity was local-
ized th rougho ut th e epithelium of th e skin at the bum m argin and 
to epithelial cells of the hair follicle (Fig 4a) . T Ilis pattern of 
staining was very similar to th ,lt seen w ith the crude an tise rum and 
was absen t ill adjacen t tissue sectio ns trea ted w ith purifIed rabbit 
IgG (Fig 4(1) , pre- absorbed antise rum , o r b locking solution alo nc 
(data not shown) . Whereas the H B-EGF was spread throug ho ut the 
regen erating surface epithelium at th e burn wound margin (Fi g 
4a), in norm al skin it w as highly localized to the basa l keratin ocytes 
of th e surface epi thelium (Fig 4c). In con tras t, derm al appendagcs, 
iden tified as hair fo ll icles and eccrin e sweat gland d ucts, stained 
positively fo r HB-EG F but did not demonstrate o bvio us difFerences 
in di stribu tion of the growth facto r between bumed and n o nbum ed 
ti ssues (Fig 4 and data not shown) . W hi le the enti re duct of the 
sw eat gland stained positively fo r HB-EGF in bo th norm al and 
burned skin , only a portion of the coiled sweat g land tubules stain ed 
positively. Using either un purified an tiserum (F ig 4d, e) or affin ity-
purified antiserum (data no t shown) , the proximal po rtion of the 
eccrine gland consistently showed in tense staining w hereas the 
distal region dem onstrated on ly sligh t or no HB-EGF im m unore-
activity (Fig 4d,e). H igh power magni fication of eccrine sweat 
glands dem o nstrated that the im muno reactivity was localized to 
epitheLial cell s lining the tu bule, with apparently higher concen tra-
tions in the lumen and luminal surfaces (Fig 4J) . Epi th elial cells of 
the epidermis and eccrin e sweat g lands also stained positively w hen 
burn wound tissue excised on day 2 was incubated w ith an 
an tiserum ra ised agains t residues 9 - 26 of HB-EGF [7] (data not 
shown) . D ermal cOllnective t issue cells reproducibly did n ot stain 
fo r HB-EGF and while blood vessels appeared to stain slightly with 
unpur ifl ed an ti-HB-EG F(26 - 41) (F ig 4d) , this fi nding was not 
substantiated using affinity- purifie d antiserum (data not show n). 
DI SCUSSION 
Altho ugh num ero us growth £1ctors and cytokin es have been im-
plicated in the wound healing response [27 ,28] , the roles p layed by 
each fac to r and th eir synergistic interactions have yet to be full y 
understood. H ere, we sho w that HB-EGF and PDGF m ay also be 
involved in healing of hum an bum wounds since they can b e 
recovered from BWF up to at least the four th day after injury. 
Eviden ce fo r the presence of HB- EGF incl uded its he parin- binding 
and EG F-R-binding pro perties, the an tagonism of its EGF- R 
b indin g by a HB-EG F-specifi c goat antiserum , the detectio n of 1 0-
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F igure 4. HB-EGF is present in the burn wound surface epithelium and shows a differential distribution "s compared to nonburned skin. 
A day 14 burn from a 17-y cauca.sia.n male was excised, fixed , sectioned, and mounted as described in Materia ls nlul Me/hads and then incub;.tcd in with 19 
J..tg/ml of either (a) affinity-purified HB-EGF(2G-41) antiserum Or «(») normal rabbit fgG . T he tissue shown in (e) is 1l0rmaillollbufllCd sbn that was incubated 
with a 1:100 dilucion of HB-EGF(26-4 1) antiserum. Additional tissue sections fro m difFerent regions ofthc burn spec imen shown in (a) and (b) were also I 
incubated with 1: [00 dilutions of eithe r (d) I-!B-EGF(26 - 41) antiserum or (e) preimmune serum . A higher magni fi c;.tio n of the immunoreactive regions in 
(d) arc shown in (fl . H , hair follicle epithe lium; B , burn wound; M, m argin of wound; S, surface epitheHul11 ; D, denni s; G, eccrine sweat g land ; V, vein; A, 
artery. Sen Ie bars, 150 J..t111 (a- c) and 30 J..t111 (I). 
to 15-kDa immunoreactive proteins on Western blots by HB-
EGF(26 -41) antiserum and by ami.no acid sequence analysis of th e 
purified protein . Evidence for the presence of PDGF included its 
relative heparin affini ty , the n eutralization of its biological activity 
by PDGF antiserum, and the de tection ofPDGF-AB using a specific 
ELISA. 
While PDGF and PDGF-Iike factors h ave previo ll sly been 
detected in a varie ty of wound fluid s, the presence of HB-EGF in 
wound fluids has not been widely reported. A recently ch aracter-
ized growth hlctor in puncture wound fluid of pigs appeared to be 
HB-EGF-like based on its heparin-affinity, target ceJl specificity, 
binding to and autophosphorylation of the EGF-R, and im muno-
detection on Western blots [19] . H owever, given the inherent 
difficulty of distinguishing between HB-EGF and AR due to their 
structural and biological similarities, our study was greatly facili-
tated by the availabili ty of two highl y specific HB-EGF antisera and 
by anuno acid sequence analysis of th e bioactive protein in HWF. 
An obvious point of inte rest is that of the time course ofHB-EGF 
production or accul11uJation ill BWF. Altho ugh we have beet! 
unable as yet to pe l'form a quantitative analysis in view of the hIck 
of hj ghly specific and sensitive assays for HB-EGF (e.g. , ELISA), we 
fOllnd from the 45 patients w ho donated BWF for tbese studies 
that, at least qualitatively, HB-EGF is detectable in BWF as early as 
day 0 and appears to be present until at leas t day 4. Unfortunately 
we have not yet been able to de termine the rate of production of 
HB-EGF on each of the days followin g injury. However, the 
sustained presence of HB-EGF in BWF and burn wound tissue 
suggests that the biological effects of HB-EGF, either alone or in 
combination with other factors such as PDGF, could be maintained 
for at least 2 wk at th e burn site. 
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Whereas glycosylated HB-EGF purified from U937 cells mi-
grates on SDS-polyacrylamide gels with aM,. of20,000-22,000 [2], 
the HB-EGF ill BWF appeared to have a M,. of 1 0,000-16,000 and 
was more simi lar in size to nonglycosylated HB-EGF. The presence 
of multiple HB-EGF bands 011 Western blots of heparin-purifi ed 
BWF is suggestive of the presence of a variety of the proteins that 
were variably truncated and/or glycosylated. Amino acid analysis of 
the HB-EGF protein in BWF that was isolated and sequenced 
clearly show that it had an N- terminal truncation of24 residu es. Of 
interest is that some of the truncated domain (i.e., residues 20-24) 
have been suggested to contribute to the heparin-binding do-
main(s) ofHB-EGF [10,291 . Since the purified protein was isolated 
by two cycles of heparin affinity chromatography, our interpreta-
tion of this data is that either (i) the truncation occurred after the 
heparin-afrinity steps; the positive stainin g by anti-HB-EGF(9-26) 
of bum wound tissues (data not shown) suggests that HB-EGF ill 
vivo exists, at least partially, in a form that is mu ch less truncated 
than that which was purified and sequenced, or (ii) additional 
heparin-binding regions are present downstream of the lys ine 
residue at position 24 of HB-EGF. Support for the latter possibility 
has come £i·om peptide mappin g and site-di rected mutagenesis , 
which have suggested that additional sites between residu es 30 and 
41 also contribute to the heparin-binding domain(s) of HB-EGF 
[10,29] . 
Since HB-EGF levels in serum and plasma are undetectable ([1] 
and data not shown), its presence in BWF is suggestive of loca l 
production at the burn wound site rather than accumulation fro m 
the circu lation. This is consistent with our immunohistochemical 
data showing that HB-EGF is present in epitheli al cells lining the 
margins of the wound and dermal appendages. Moreover, COI11-
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pared with normal skin which exhibits HB-EGF staining in the 
basal epithelium, there is a striking difference at the burn wound site 
in that HB-EGF is uniformaUy distributed throughout the entire 
epithelium. Thus thermal irtiury appears to be associated with a 
distinct distribution of HB-EGF, as well as HB-EGF accumulation 
in blister fluid. 
Although the bas is for the differential staining for HB-EGF in 
eccrine sweat glands was not investigated further, it may be 
relevant that the proximal portions of these glands are epithelial in 
nature whereas the distal portions are composed of secretory or 
myoepithelial cells. Since the transition between secretory and 
ductal epithelial cells is histologically abrupt, our data may be 
suggestive of differences in HB-EGF production by these distinct 
ceU populations. While we canllot eliminate the possibility that 
other cell types produce lower nondetectable amounts of HB-EGF 
in the burn wound, it is of interest that high levels of EGF-R 
expression have been demonstrated in the early post-burn period in 
humans in marginal keratinocytes, in adjacent hypertrophic epithe-
limn and in marginal and non-marginal hair follicles and in sweat 
ducts and sebaceous gla.nds [30] . Therefore, HB-EGF produced by 
surface and glandular epithelial cells may act at the burn site 
through autocrine, paracrine, orjuxtacrine mechanisms to stimulate 
epithelial regeneration. 
T he fmding that HB-EGF is produced ill IJ;IJO in the partial-
thickness burn wound adds this molecule to the growing list of 
cytokin es and growth factors that may regulate the wound healing 
process. Since HB-EGF is present in BWF and undergoes epithelial 
redistribution in the vicinity of the burn wound, it may play an 
integral role in the normal healing response to thermal injury. 
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